CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- SC 13G Stake Amended Statement of Ownership
- 8-K Event Shareholder vote results
- 4 Gift Chief Commercial Officer gave 1,580 shares (gift)
- 4 Gift Chief Legal Officer gave 500 shares (gift)
- 4 Planned sale Chief Financial Officer sold 32,500 shares at an average $26.94 ($875,451)
- 4 Planned sale Chief Medical Officer sold 11,965 shares at $29.03 ($347,358)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4/A Conversion Chief Financial Officer acquired 19,482 shares (conversion)
- 3/A Insider 3/A
- 4 Planned sale Chief Medical Officer sold 49,579 shares at an average $30.54 ($1,513,942)
- 144 Insider Sale of Securities
- SC 13D/A Stake Beneficial Ownership Report
Page 15 of 23 · 446 filings